Literature DB >> 12517841

Occurrence and phenotypic characteristics of extended-spectrum beta-lactamases among members of the family Enterobacteriaceae at the Tel-Aviv Medical Center (Israel) and evaluation of diagnostic tests.

Shiri Navon-Venezia1, Orly Hammer-Munz, David Schwartz, Dan Turner, Boris Kuzmenko, Yehuda Carmeli.   

Abstract

We assessed the prevalence and phenotypic characteristics of extended-spectrum beta-lactamase (ESBL) producers among cefuroxime-resistant (CXM-R) (MIC > or = 32 micro g/ml) members of the family Enterobacteriaceae in our institution. The 438 CXM-R clinical isolates obtained from nonurine sources among inpatients were screened. ESBL production was confirmed by disk diffusion assay using cefpodoxime (CPD), cefotaxime (CTX), and ceftazidime (CTZ) with and without clavulanate (CLAV). A difference of > or =5 mm in the size of the zone of inhibition in the presence of CLAV for at least one of the agents was considered representative of the ESBL phenotype: 186 isolates (42.5%) were confirmed as ESBL producers. The isolates tested and the rates of ESBL producers were as follows: Klebsiella spp. (n = 81), 79%; Proteus spp. (n = 58), 62%; Escherichia coli (n = 64), 53%; Enterobacter spp. (n = 69), 42%; Serratia spp. (n = 70), 14%; Citrobacter spp. (n = 25), 24%; Providencia spp. (n = 21), 24%; Morganella spp. (n = 41), 5%; and Kluyvera (n = 3), 0%. The overall sensitivity of isolated ESBL confirmatory tests was 79% for CPD-CLAV, 66% for CTZ-CLAV, and 91% for CTX-CLAV. Sensitivities of CTZ-CLAV confirmatory tests for Klebsiella spp., Proteus spp., E. coli, and Enterobacter spp. were 84, 22, 76, and 62%, respectively, and those for CTX-CLAV were 95, 97, 94, and 83%, respectively. They were 90% for CPD-CLAV and CTZ-CLAV, 95% for CPD-CLAV and CTX-CLAV, and 100% for CTZ-CLAV and CTX-CLAV. ESBL production was highly prevalent among Enterobacteriaceae. Using resistance to CXM as an ESBL screening criterion is a suitable option in high-incidence areas where Klebsiella spp. are not the dominant ESBL producers. This screening criterion may simplify the screening test and improve its sensitivity, although at the price of testing more isolates. The CTX-CLAV combination confirmed ESBL producers better than the CTZ-CLAV combination, with sensitivity varying between species. Combined CTZ-CLAV and CTX-CLAV testing detected all these strains; CPD-CLAV provided no additional benefit.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12517841      PMCID: PMC149636          DOI: 10.1128/JCM.41.1.155-158.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  18 in total

1.  Antimicrobial resistance in Enterobacteriaceae in Brooklyn, NY: epidemiology and relation to antibiotic usage patterns.

Authors:  G Saurina; J M Quale; V M Manikal; E Oydna; D Landman
Journal:  J Antimicrob Chemother       Date:  2000-06       Impact factor: 5.790

Review 2.  Plasmid-determined AmpC-type beta-lactamases.

Authors:  Alain Philippon; Guillaume Arlet; George A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs.

Authors:  T Spanu; F Luzzaro; M Perilli; G Amicosante; A Toniolo; G Fadda
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

Review 4.  Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Authors:  P A Bradford
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

5.  Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region.

Authors:  P L Winokur; R Canton; J M Casellas; N Legakis
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

6.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

Review 7.  Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.

Authors:  D L Paterson; W C Ko; A Von Gottberg; J M Casellas; L Mulazimoglu; K P Klugman; R A Bonomo; L B Rice; J G McCormack; V L Yu
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

Review 8.  Increasing prevalence of antimicrobial resistance in intensive care units.

Authors:  S K Fridkin
Journal:  Crit Care Med       Date:  2001-04       Impact factor: 7.598

Review 9.  Extended-spectrum beta-lactamases and other enzymes providing resistance to oxyimino-beta-lactams.

Authors:  G A Jacoby
Journal:  Infect Dis Clin North Am       Date:  1997-12       Impact factor: 5.982

10.  Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes.

Authors:  E Lautenbach; J B Patel; W B Bilker; P H Edelstein; N O Fishman
Journal:  Clin Infect Dis       Date:  2001-03-26       Impact factor: 9.079

View more
  16 in total

1.  Evaluation of an accelerated protocol for detection of extended-spectrum beta-lactamase-producing gram-negative bacilli from positive blood cultures.

Authors:  Shiri Navon-Venezia; Azita Leavitt; Ronen Ben-Ami; Yuval Aharoni; Mitchell J Schwaber; David Schwartz; Yehuda Carmeli
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

2.  Extended-spectrum beta-lactamases among Enterobacter isolates obtained in Tel Aviv, Israel.

Authors:  Jacob Schlesinger; Shiri Navon-Venezia; Inna Chmelnitsky; Orly Hammer-Münz; Azita Leavitt; Howard S Gold; Mitchell J Schwaber; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

3.  Screening for extended-spectrum beta-lactamase-producing pathogenic enterobacteria in district general hospitals.

Authors:  Nteimam Jonathan
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

4.  High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae.

Authors:  Mitchell J Schwaber; Shiri Navon-Venezia; David Schwartz; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

5.  CTX-M-2 and a new CTX-M-39 enzyme are the major extended-spectrum beta-lactamases in multiple Escherichia coli clones isolated in Tel Aviv, Israel.

Authors:  Inna Chmelnitsky; Yehuda Carmeli; Azita Leavitt; Mitchell J Schwaber; Shiri Navon-Venezia
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

6.  National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases.

Authors:  Dror Marchaim; Tamar Gottesman; Orna Schwartz; Maya Korem; Yasmin Maor; Galia Rahav; Rebekah Karplus; Tsipora Lazarovitch; Eyal Braun; Hana Sprecher; Tamar Lachish; Yonit Wiener-Well; Danny Alon; Michal Chowers; Pnina Ciobotaro; Rita Bardenstein; Alona Paz; Israel Potasman; Michael Giladi; Vered Schechner; Mitchell J Schwaber; Shiri Klarfeld-Lidji; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2010-09-13       Impact factor: 5.191

7.  Four variants of the Citrobacter freundii AmpC-Type cephalosporinases, including novel enzymes CMY-14 and CMY-15, in a Proteus mirabilis clone widespread in Poland.

Authors:  Elzbieta Literacka; Joanna Empel; Anna Baraniak; Ewa Sadowy; Waleria Hryniewicz; Marek Gniadkowski
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

8.  Extended-spectrum beta-lactamase-producing Shigella strains in Israel, 2000-2004.

Authors:  V Vasilev; R Japheth; R Yishai; N Andorn; L Valinsky; S Navon-Venezia; I Chmelnitsky; Y Carmeli; D Cohen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-03       Impact factor: 3.267

9.  Ertapenem resistance among extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae isolates.

Authors:  Azita Leavitt; Inna Chmelnitsky; Raul Colodner; Itzhak Ofek; Yehuda Carmeli; Shiri Navon-Venezia
Journal:  J Clin Microbiol       Date:  2009-02-11       Impact factor: 5.948

10.  Protocol for the accelerated detection of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae strains from blood cultures.

Authors:  S Navon-Venezia; R Ben-Ami; M J Schwaber; A Leavitt; D Schwartz; Y Carmeli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-02-07       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.